Cargando…
Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension
BACKGROUND: There are theoretical concerns that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could increase the risk of severe Covid-19. OBJECTIVE: To determine if ACEIs and ARBs are associated with an increased risk of Covid-19 hospitalization overall, o...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486159/ https://www.ncbi.nlm.nih.gov/pubmed/34599472 http://dx.doi.org/10.1007/s11606-021-07155-z |
_version_ | 1784577686367109120 |
---|---|
author | Graham, David J. Izurieta, Hector S. Muthuri, Stella G. Zhang, Di Sandhu, Alexander T. Lu, Yun Zhao, Yueqin Feng, Yuhui Eworuke, Efe Lyu, Hai Gandotra, Charu Smith, Elizabeth R. Avagyan, Armen Wernecke, Michael Kelman, Jeffrey A. Forshee, Richard A. MaCurdy, Thomas E. |
author_facet | Graham, David J. Izurieta, Hector S. Muthuri, Stella G. Zhang, Di Sandhu, Alexander T. Lu, Yun Zhao, Yueqin Feng, Yuhui Eworuke, Efe Lyu, Hai Gandotra, Charu Smith, Elizabeth R. Avagyan, Armen Wernecke, Michael Kelman, Jeffrey A. Forshee, Richard A. MaCurdy, Thomas E. |
author_sort | Graham, David J. |
collection | PubMed |
description | BACKGROUND: There are theoretical concerns that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could increase the risk of severe Covid-19. OBJECTIVE: To determine if ACEIs and ARBs are associated with an increased risk of Covid-19 hospitalization overall, or hospitalization involving intensive care unit (ICU) admission, invasive mechanical ventilation, or death. DESIGN: Observational case-control study. PARTICIPANTS: Medicare beneficiaries aged ≥ 66 years with hypertension, treated with ACEIs, ARBs, calcium channel blockers (CCBs), or thiazide diuretics. MAIN MEASURES: Adjusted odds ratios (OR) and 95% confidence intervals (CI) for the outcomes of Covid-19 hospitalization, or hospitalization involving ICU admission, invasive mechanical ventilation, or death. RESULTS: A total of 35,300 cases of hospitalized Covid-19 were matched to 228,228 controls on calendar date and neighborhood of residence. The median age of cases was 79 years, 57.4% were female, and the median duration of hospitalization was 8 days (interquartile range 5–12). ACEIs and ARBs were associated with a slight reduction in Covid-19 hospitalization risk compared with treatment with other first-line antihypertensives (OR for ACEIs 0.95, 95% CI 0.92–0.98; OR for ARBs 0.94, 95% CI 0.90–0.97). Similar results were obtained for hospitalizations involving ICU admission, invasive mechanical ventilation, or death. There were no meaningful differences in risk for ACEIs compared with ARBs. In an analysis restricted to monotherapy with a first-line agent, CCBs were associated with a small increased risk of Covid-19 hospitalization compared with ACEIs (OR 1.09, 95% CI 1.04–1.14), ARBs (OR 1.10, 95% CI 1.05–1.15), or thiazide diuretics (OR 1.11, 95% CI 1.03–1.19). CONCLUSIONS: ACEIs and ARBs were not associated with an increased risk of Covid-19 hospitalization or with hospitalization involving ICU admission, invasive mechanical ventilation, or death. The finding of a small increased risk of Covid-19 hospitalization with CCBs was unexpected and could be due to residual confounding. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-021-07155-z. |
format | Online Article Text |
id | pubmed-8486159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-84861592021-10-04 Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension Graham, David J. Izurieta, Hector S. Muthuri, Stella G. Zhang, Di Sandhu, Alexander T. Lu, Yun Zhao, Yueqin Feng, Yuhui Eworuke, Efe Lyu, Hai Gandotra, Charu Smith, Elizabeth R. Avagyan, Armen Wernecke, Michael Kelman, Jeffrey A. Forshee, Richard A. MaCurdy, Thomas E. J Gen Intern Med Original Research BACKGROUND: There are theoretical concerns that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could increase the risk of severe Covid-19. OBJECTIVE: To determine if ACEIs and ARBs are associated with an increased risk of Covid-19 hospitalization overall, or hospitalization involving intensive care unit (ICU) admission, invasive mechanical ventilation, or death. DESIGN: Observational case-control study. PARTICIPANTS: Medicare beneficiaries aged ≥ 66 years with hypertension, treated with ACEIs, ARBs, calcium channel blockers (CCBs), or thiazide diuretics. MAIN MEASURES: Adjusted odds ratios (OR) and 95% confidence intervals (CI) for the outcomes of Covid-19 hospitalization, or hospitalization involving ICU admission, invasive mechanical ventilation, or death. RESULTS: A total of 35,300 cases of hospitalized Covid-19 were matched to 228,228 controls on calendar date and neighborhood of residence. The median age of cases was 79 years, 57.4% were female, and the median duration of hospitalization was 8 days (interquartile range 5–12). ACEIs and ARBs were associated with a slight reduction in Covid-19 hospitalization risk compared with treatment with other first-line antihypertensives (OR for ACEIs 0.95, 95% CI 0.92–0.98; OR for ARBs 0.94, 95% CI 0.90–0.97). Similar results were obtained for hospitalizations involving ICU admission, invasive mechanical ventilation, or death. There were no meaningful differences in risk for ACEIs compared with ARBs. In an analysis restricted to monotherapy with a first-line agent, CCBs were associated with a small increased risk of Covid-19 hospitalization compared with ACEIs (OR 1.09, 95% CI 1.04–1.14), ARBs (OR 1.10, 95% CI 1.05–1.15), or thiazide diuretics (OR 1.11, 95% CI 1.03–1.19). CONCLUSIONS: ACEIs and ARBs were not associated with an increased risk of Covid-19 hospitalization or with hospitalization involving ICU admission, invasive mechanical ventilation, or death. The finding of a small increased risk of Covid-19 hospitalization with CCBs was unexpected and could be due to residual confounding. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-021-07155-z. Springer International Publishing 2021-10-01 2021-12 /pmc/articles/PMC8486159/ /pubmed/34599472 http://dx.doi.org/10.1007/s11606-021-07155-z Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021 |
spellingShingle | Original Research Graham, David J. Izurieta, Hector S. Muthuri, Stella G. Zhang, Di Sandhu, Alexander T. Lu, Yun Zhao, Yueqin Feng, Yuhui Eworuke, Efe Lyu, Hai Gandotra, Charu Smith, Elizabeth R. Avagyan, Armen Wernecke, Michael Kelman, Jeffrey A. Forshee, Richard A. MaCurdy, Thomas E. Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension |
title | Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension |
title_full | Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension |
title_fullStr | Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension |
title_full_unstemmed | Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension |
title_short | Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension |
title_sort | risk of covid-19-related hospitalization and more severe outcomes in medicare beneficiaries treated with renin-angiotensin-aldosterone system inhibitors for hypertension |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486159/ https://www.ncbi.nlm.nih.gov/pubmed/34599472 http://dx.doi.org/10.1007/s11606-021-07155-z |
work_keys_str_mv | AT grahamdavidj riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT izurietahectors riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT muthuristellag riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT zhangdi riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT sandhualexandert riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT luyun riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT zhaoyueqin riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT fengyuhui riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT eworukeefe riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT lyuhai riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT gandotracharu riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT smithelizabethr riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT avagyanarmen riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT werneckemichael riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT kelmanjeffreya riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT forsheericharda riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension AT macurdythomase riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension |